Skip to main content
. 2019 May 29;24(10):1223–1230. doi: 10.1007/s10147-019-01473-3

Fig. 5.

Fig. 5

Kaplan–Meier estimates of progression-free survival (PFS) in the full analysis set of metastatic colorectal cancer (mCRC) patients treated with bevacizumab versus anti-EGFR (cetuximab or panitumumab) as first-line treatment. Median PFS was 5.5 months (95% CI 4.43–10.33) and 6.8 months (95% CI 3.97–37.33) for the bevacizumab group and anti-EGFR group, respectively. Bev bevacizumab. p = 0.4, log-rank test